Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell signals could help rebuild jawbone for dental implants

NCT ID NCT04998058

NEW Symptom relief Sponsor: Pontificia Universidade Católica do Rio Grande do Sul Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether signaling molecules made by a patient's own fat-derived stem cells can help synthetic bone grafts build stronger jawbone. The trial enrolls 20 adults with severe upper-jaw bone loss who need sinus floor augmentation before dental implants. Each participant receives the stem cell signaling molecules on one side of the jaw and a plain saline mixture on the other, so the two approaches can be compared. The team measures bone density, volume, and maturity using CT scans and tissue samples over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
signaling molecules collected from a patient's own fat-derived mesenchymal stem cells, mixed with a synthetic bone substitute
What this could lead to
If it works, this could give dental surgeons a way to grow more reliable bone for implants using a patient's own cells, without extra donor surgery.
What could go wrong
This is a small Phase 1 trial with 20 people, so it can only hint at whether the approach helps. Collecting and processing each patient's cells is complex, and the added signaling molecules may not improve bone growth enough to matter.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2027

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients \>35 years-old. * presenting highly atrophic fully edentulous maxilla (residual bone height \<5 mm). * In need of bilateral sinus floor augmentation aiming full mouth implant-supported rehabilitation. * having teeth extraction at least 8 weeks prior to bone augmentation. Exclusion Criteria: * smokers, illicit drug users and alcohol daily consumers. * patients with metabolic and/or systemic diseases leading to impaired healing (e.g. decompensated diabetes, leukocyte or coagulation disorders, immunosuppression). * history of radiotherapy in the head or neck region. * bisphosphonate-based therapy recipients. * intolerant to general/local anesthesia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar bone atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss bone resorption disease periodontal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar bone atrophy Alveolar bone loss Bone loss, alveolar Bone loss, osteoclastic Grafting bone

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pontificia Universidade Católica do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, 90619-900, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.